Back
Innate Pharma SA 10K Form
Sell
16
IPHA
Innate Pharma SA
Last Price:
2.26
Seasonality Move:
-4.78%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive IPHA News And Ratings
See the #1 stock for the next 7 days that we like better than IPHA
IPHA Financial Statistics
Sales & Book Value
| Annual Sales: | $56.19M |
|---|---|
| Cash Flow: | $0 |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.38 |
| Price / Book: | 5.9 |
Profitability
| EPS (TTM): | -0.45230 |
|---|---|
| Net Income (TTM): | $-36.67M |
| Gross Margin: | $61.43M |
| Return on Equity: | -72.79% |
| Return on Assets: | -18.89% |
Innate Pharma SA Earnings Forecast
Key Innate Pharma SA Financial Ratios
- The Gross Profit Margin over the past 16 years for IPHA is 95.79%.
- The Selling, General & Administrative Expenses for IPHA have been equal to 22.64% of Gross Profit Margin.
- The Research & Development expenses have been 107.94% of Revenue.
- The Interest Expense is -8.45% of Operating Income.
- The Net Earning history of IPHA is -14.59% of Total Revenues.
- Per Share Earnings over the last 19 years have been positive in 11 years.
Innate Pharma SA Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | IPHA |
| Website: | innate-pharma.com |
Debt
| Debt-to-Equity Ratio: | 1.23 |
|---|---|
| Current Ratio: | 2.92 |
| Quick Ratio: | 2.76 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
IPHA Technical Analysis vs Fundamental Analysis
Sell
16
Innate Pharma SA (IPHA)
is a Sell
Is Innate Pharma SA a Buy or a Sell?
-
Innate Pharma SA stock is rated a Sell
The current Innate Pharma SA [IPHA] share price is $2.25. The Score for IPHA is 16, which is 68% below its historic median score of 50, and infers higher risk than normal.